Point72 Europe London LLP Buys 24,200 Shares of Qiagen (NYSE:QGEN)

Point72 Europe London LLP lifted its stake in shares of Qiagen (NYSE:QGEN) by 5.3% during the second quarter, Holdings Channel.com reports. The firm owned 483,558 shares of the company’s stock after buying an additional 24,200 shares during the period. Qiagen accounts for approximately 1.6% of Point72 Europe London LLP’s holdings, making the stock its 12th largest position. Point72 Europe London LLP’s holdings in Qiagen were worth $19,869,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Qiagen by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock worth $382,856,000 after buying an additional 83,371 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Qiagen by 20.1% during the fourth quarter. Wellington Management Group LLP now owns 7,271,828 shares of the company’s stock valued at $316,463,000 after acquiring an additional 1,217,712 shares during the period. Nuance Investments LLC boosted its holdings in Qiagen by 17.3% in the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock valued at $216,606,000 after acquiring an additional 778,005 shares during the last quarter. FIL Ltd increased its position in Qiagen by 8.5% in the fourth quarter. FIL Ltd now owns 5,099,140 shares of the company’s stock worth $221,784,000 after purchasing an additional 399,965 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Qiagen by 0.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock worth $151,526,000 after purchasing an additional 26,078 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Trading Up 0.9 %

QGEN opened at $44.86 on Wednesday. The firm’s fifty day moving average is $45.03 and its two-hundred day moving average is $43.47. The firm has a market cap of $10.24 billion, a PE ratio of 30.08, a price-to-earnings-growth ratio of 3.17 and a beta of 0.39. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to analysts’ expectations of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 EPS. Equities research analysts anticipate that Qiagen will post 2.15 EPS for the current year.

Analyst Upgrades and Downgrades

QGEN has been the topic of several recent research reports. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research note on Thursday, June 27th. Robert W. Baird raised their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. upped their target price on shares of Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $51.10.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.